{'fraction_non_alphanumeric': 0.040840140023337225, 'fraction_numerical': 0.0338389731621937, 'mean_word_length': 4.958333333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Inhibitory effects of indomethacin on growth and proliferation of gastric carcinoma cells KATO III.

The effects of indomethacin on growth and proliferation of gastric carcinoma cells KATO III were examined. Indomethacin (10(-4) and 10(-3) M) significantly inhibited cell growth and these effects were not affected by treatment with 16,16-dimethyl prostaglandin E2 (3 x 10(-7) M and 3 x 10(-6) M). Indomethacin 10(-3) M significantly reduced cell viability and completely inhibited cell growth. Indomethacin 10(-4) M did not affect cell viability and its inhibitory effect of cell growth became apparent on the fifth day of culture. Indomethacin 10(-4) M reduced BrdU labeling index within 2 hours. These results suggest that indomethacin inhibited growth and proliferation of gastric carcinoma cells KATO III. This effect is not mediated by prostaglandins.